指南与共识前列腺癌

前列腺癌挽救治疗:AUA/ASTRO/SUO指南第一部分:引言及根治性前列腺切除术后疑似生化复发时的治疗决策

Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.
指南 / 共识 · J Urol · 2024-02-29

本指南由AUA、ASTRO和SUO联合制定,基于截至2022年7月及2023年7月更新的系统检索,针对根治性前列腺切除术后疑似生化复发患者,提供循证与共识声明以辅助治疗决策。第一部分聚焦于挽救治疗决策,后续部分涉及治疗实施及放疗或局灶治疗后复发等管理。

要点

  • 指南涵盖根治性前列腺切除术后疑似生化复发时的挽救治疗决策。
  • 推荐意见基于证据与共识,旨在辅助临床医生决策。
  • 诊断工具、生物标志物及放疗技术进展将影响长期控瘤与毒性平衡。

核心结论

  • 诊断工具(尤其影像)、生物标志物、放疗实施及生物调控等领域的进展,将为患者长期控制癌症并最小化毒性提供新机会。

研究设计与样本

  • 由AUA、ASTRO和SUO联合组成的前列腺癌挽救治疗专家组制定,基于证据与共识的声明。

主要发现

  • 系统评价基于Ovid MEDLINE(1946年至2022年7月21日)、Cochrane对照试验中心注册库(至2022年8月)及Cochrane系统评价数据库(至2022年8月)的检索,并于2023年7月26日进行更新检索。

关键数值与推荐

  • 指南针对初始根治性局部治疗后出现生化复发的临床局限性前列腺癌患者提供指导。

临床怎么用

  • 原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a recurrence following prior treatment with curative intent. This is Part I of a three-part series focusing on treatment decision-making at the time of suspected biochemical recurrence (BCR) after radical prostatectomy (RP). Please refer to Part II for discussion of treatment delivery for non-metastatic BCR after RP and Part III for discussion of evaluation and management of recurrence after radiotherapy (RT) and focal therapy, regional recurrence, and oligometastasis. MATERIALS AND METHODS: The systematic review that informs this Guideline was based on searches in Ovid MEDLINE (1946 to July 21, 2022), Cochrane Central Register of Controlled Trials (through August 2022), and Cochrane Database of Systematic Reviews (through August 2022). Update searches were conducted on July 26, 2023. Searches were supplemented by reviewing electronic database reference lists of relevant articles. RESULTS: In a collaborative effort between AUA, ASTRO, and SUO, the Salvage Therapy for Prostate Cancer Panel developed evidence- and consensus-based statements to provide guidance for the care of patients who experience BCR after initial definitive local therapy for clinically localized disease. CONCLUSIONS: Advancing work in the area of diagnostic tools (particularly imaging), biomarkers, radiation delivery, and biological manipulation with the evolving armamentarium of therapeutic agents will undoubtedly present new opportunities for patients to experience long-term control of their cancer while minimizing toxicity.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. J Urol. 2024. PMID: 38421253. doi:10.1097/JU.0000000000003892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。